ClinicalTrials.gg
CompletedNCT02675998Updated Aug 10, 2020Results posted

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

A Phase 3 interventional study of Tenapanor and Placebo in Hyperphosphatemia, sponsored by Ardelyx. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-08-10.

Sponsored by Ardelyx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
219
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing tenapanor in Hyperphosphatemia — none open to participants now, none under way, none of them phase 3. tenapanor · Hyperphosphatemia.

Enrollment
4th of 13
219 · median 172
Started
2016
the only one that year
Phase 3
6 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
6 of 13
Ardelyx

Among the 13 studies testing tenapanor in Hyperphosphatemia, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 3, and was the 2nd registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

None of the 13 studies testing tenapanor in Hyperphosphatemia is open now. The open studies under Hyperphosphatemia, anywhere →

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing tenapanor in Hyperphosphatemia as a file.
02

Study summary

This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat hyperphosphatemia in end-stage renal disease patients on hemodialysis (ESRD-HD). Subjects who qualify are randomized into the study will either receive 3 mg BID, 10 mg BID, or a titration regimen of tenapanor.

Read the detailed description

The study consists of a screening visit, a wash out period of up to 3 weeks, when existing phosphate lowering medication is withheld, an 8-week treatment period, in which all groups receive tenapanor, and a 4-week placebo-controlled, randomized withdrawal period, during which patients are re-randomized 1:1 to either remain on their current tenapanor treatment or placebo.

Depending on the increase in serum phosphate levels, subjects can be randomized 1,2, or 3 weeks after being taken off their phosphate lowering medication.

03

Conditions studied

  • Hyperphosphatemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 80 years old
  • Females must be non-pregnant, non-lactating, and either be for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable methods.
  • Males must agree to avoid fathering a child and agree to use an appropriate method of contraception
  • Chronic maintenance hemodialysis 3x/week for at least 3 months
  • Kt/V ≥ 1.3 at most recent measurement prior to screening
  • Prescribed and taking at least 3 doses of phosphate binder per day
  • Serum phosphate levels should be between 4.0 and 7.0 mg/dL (inclusive) at screening
  • For randomization in the study, after 1 week wash-out of phosphate binders, subjects must have serum phosphate level of at least 9 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value
  • For randomization in the study, after 2 or 3 weeks wash-out of phosphate binders, subjects must have serum phosphate level of at least 6 mg/dL but below 10 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value

Exclusion criteria

Exclusion Criteria:

  • Severe hyperphosphatemia defined as >10 mg/dL on Phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening
  • Serum parathyroid hormone >1200 pg/mL
  • Persistent metabolic acidosis defined as serum carbon dioxide \<18 mmol/L from two consecutive measurements during screening and
  • Clinical signs of hypovolemia at randomization
  • History of inflammatory bowel disease (IBD) or diarrhea predominant irritable bowel syndrome (IBS-D)
  • Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period
  • Diarrhea or loose stools during the week before randomization defined as BSFS ≥ 6 and frequency ≥ 3 for 2 or more days
  • Any evidence of or treatment of within one year, excluding non-melanomatous malignancies of the skin
  • Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator
  • \< 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
219 participants (actual)

Study arms

  • Experimental
    3mg BID

    Tenapanor, 3mg BID (6mg total)

    Drug: Tenapanor

  • Experimental
    10mg BID

    Tenapanor, 10mg BID (20mg total)

    Drug: Tenapanor

  • Experimental
    Dose Titration

    Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question

    Drug: Tenapanor

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • Also known as: RDX5791, AZD1722

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms

    Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period

    Time frame: 4 weeks

Secondary outcomes

  1. Change in Serum Phosphate During 8-Week Treatment Period

    Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set

    Time frame: Baseline and 8 weeks

07

Results

Posted Aug 10, 2020

Participant flow

8-Week Treatment Period
Participant flow — 8-Week Treatment Period
Milestone3mg BID10mg BID30 mg Dose TitrationRandomized Withdrawal Period Placebo
Started7473720
Completed5754530
Not completed1719190
Withdrew: Adverse event6560
Withdrew: Withdrawal by subject3330
Withdrew: Lack of efficacy2530
Withdrew: Physician decision1020
Withdrew: Gi side effects1420
Withdrew: Protocol violation1110
Withdrew: Other3120
4-Week Randomized Withdrawal Period
Participant flow — 4-Week Randomized Withdrawal Period
Milestone3mg BID10mg BID30 mg Dose TitrationRandomized Withdrawal Period Placebo
Started25233482
Completed24223274
Not completed1128
Withdrew: Lack of efficacy0113
Withdrew: Adverse event0013
Withdrew: Protocol violation0001
Withdrew: Physician decision1000
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryPlacebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms

Serum phosphorus difference between placebo and tenapanor in the change from the end of the 8 week treatment period to the end of the randomized withdrawal period in Efficacy Analysis Set. The efficacy analysis was pre-defined to be a pooled analysis of all tenapanor treated patients with a minimum of a 1.2 mg/dL decrease in serum phosphorus during the 8-week treatment period

Time frame:
4 weeks
Reported as:
Least squares mean · mg/dL
Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms
mg/dL3mg BID10mg BID30 mg Dose TitrationPlacebo
Placebo Adjusted Change in Serum Phosphate During Randomized Withdrawal Period From Pooled Tenapanor Arms——1.4 ± 0.230.6 ± 0.21
Statistical analysis
  • 30 mg Dose Titration vs Placebo · ANCOVA · p = 0.01
SecondaryChange in Serum Phosphate During 8-Week Treatment Period

Serum phosphorus difference between baseline (end of washout period) to the end of the 8 week treatment period in ITT analysis set

Time frame:
Baseline and 8 weeks
Reported as:
Least squares mean · mg/dL
Change in Serum Phosphate During 8-Week Treatment Period
mg/dL3mg BID10mg BID30 mg Dose TitrationPlacebo
Change in Serum Phosphate During 8-Week Treatment Period-1.1 ± 0.17-1.1 ± 0.17-1.1 ± 0.18—
Statistical analysis
  • 3mg BID · ANCOVA · p = <0.001
  • 10mg BID · ANCOVA · p = <0.001
  • 30 mg Dose Titration · ANCOVA · p = <0.001

Adverse events

Collected over 12 weeks. The first 8 weeks were tenapanor only and during the last 4 weeks half of the tenapanor-treated patients from the first 8 weeks were randomized to receive placebo. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3mg BID1/74 (1.4%)1/74 (1.4%)22/74 (29.7%)
10mg BID0/73 (0%)0/73 (0%)30/73 (41.1%)
30 mg Dose Titration0/72 (0%)0/72 (0%)34/72 (47.2%)
Randomized Withdrawal Period Placebo0/82 (0%)0/82 (0%)7/82 (8.5%)
Most frequent serious events
Most frequent serious events
Event3mg BID10mg BID30 mg Dose TitrationRandomized Withdrawal Period Placebo
DiarrheaGastrointestinal disorders1/740/730/720/82
Most frequent other events
Most frequent other events
Event3mg BID10mg BID30 mg Dose TitrationRandomized Withdrawal Period Placebo
DiarrheaGastrointestinal disorders22/7430/7334/727/82

Baseline characteristics

This was a placebo-controlled randomized withdrawal study. All participants received drug during the first 8-weeks (no placebo) and then were randomized 1:1 to either remain on tenapanor dose or receive placebo.

Age, Continuous
Age, Continuous(years)3mg BID10mg BIDDose TitrationPlaceboTotal
Mean55.7 ± 11.4957.4 ± 10.8154.2 ± 10.87—55.8 ± 11.09
Sex: Female, Male
Sex: Female, Male(Participants)3mg BID10mg BIDDose TitrationPlaceboTotal
Female283924—91
Male463448—128
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)3mg BID10mg BIDDose TitrationPlaceboTotal
Hispanic or Latino13819—40
Not Hispanic or Latino616553—179
Unknown or Not Reported000—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)3mg BID10mg BIDDose TitrationPlaceboTotal
American Indian or Alaska Native110—2
Asian200—2
Native Hawaiian or Other Pacific Islander121—4
Black or African American404540—125
White302531—86
More than one race000—0
Unknown or Not Reported000—0
Body Mass Index
Body Mass Index(m/kg^2)3mg BID10mg BIDDose TitrationPlaceboTotal
Mean32.5 ± 8.5233.6 ± 8.5033.4 ± 8.15—33.1 ± 8.37
08

Study locations

32 sites
  • Ardelyx Investigative Site 429
    Huntsville, Alabama 35805, United States
  • Ardelyx Investigative Site 425
    Riverside, California 92505, United States
  • Ardelyx Clinical Site 403
    Denver, Colorado 80230, United States
  • Ardelyx Investigative Site 410
    Lauderdale Lakes, Florida 33313, United States
  • Ardelyx Investigative Site 430
    Miami, Florida 33173, United States
  • Ardelyx Investigative Site 427
    Meridian, Idaho 83642, United States
  • Ardelyx Investigative Site 432
    Shreveport, Louisiana 71101, United States
  • Ardelyx Investigative Site 415
    Bethesda, Maryland 20814, United States
  • Ardelyx Investigative Site 402
    Kalamazoo, Michigan 49008, United States
  • Ardelyx Investigative Site 424
    Roseville, Michigan 48066, United States
  • Ardelyx Investigative Site 409
    Brookhaven, Mississippi 39601, United States
  • Ardelyx Investigative Site 417
    Columbus, Mississippi 39705, United States
  • Ardelyx Investigative Site 431
    Tupelo, Mississippi 38801, United States
  • Ardelyx Investigative Site 423
    Saint Louis, Missouri 63136, United States
  • Ardelyx Investigative Site 416
    Albuquerque, New Mexico 87109, United States
  • Ardelyx Investigative Site 419
    Bronx, New York 10803, United States
  • Ardelyx Investigative Site 408
    Asheville, North Carolina 28805, United States
  • Ardelyx Investigative Site 411
    Charlotte, North Carolina 28204, United States
  • Ardelyx Investigative Site 420
    New Bern, North Carolina 28562, United States
  • Ardelyx Investigative Site 426
    Raleigh, North Carolina 27609, United States
  • Ardelyx Investigative Site 412
    Wilmington, North Carolina 28403, United States
  • Ardelyx Investigative Site 414
    Bethlehem, Pennsylvania 18017, United States
  • Ardelyx Investigative Site 404
    Columbia, South Carolina 29203, United States
  • Ardelyx Investigative Site 421
    Orangeburg, South Carolina 29118, United States
  • Ardelyx Investigative Site 428
    Sumter, South Carolina 29150, United States
  • Ardelyx Investigative Site 413
    Knoxville, Tennessee 37923, United States
  • Ardelyx Investigative Site 418
    Nashville, Tennessee 37205, United States
  • Ardelyx Investigative Site 406
    Austin, Texas 78758, United States
  • Ardelyx Investigative Site 405
    Bellville, Texas 77418, United States
  • Ardelyx Investigative Site 422
    San Antonio, Texas 78215, United States
  • Ardelyx Investigative Site 407
    San Antonio, Texas 78229, United States
  • Ardelyx Investigative Site 401
    Saint George, Utah 84790, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Dec 2016 and a completion of Jan 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2016
First posted
Feb 5, 2016
Start
Jan 2016
Primary completionActual
Dec 2016
CompletionActual
Jan 17, 2018
Results first posted
Aug 10, 2020
Last update
Aug 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02675998
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Feb 5, 2016
Start date
Jan 2016
Primary completion
Dec 2016
Completion
Jan 17, 2018
Results posted
Aug 10, 2020
Last update
Aug 10, 2020

Study contacts

David P Rosenbaum, Ph.D.
study chair · Ardelyx, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion